Skip to main content
Skip to content
Case File
efta-efta01385523DOJ Data Set 10Correspondence

EFTA Document EFTA01385523

Date
Unknown
Source
DOJ Data Set 10
Reference
efta-efta01385523
Pages
0
Persons
0
Integrity
Loading PDF viewer...

Summary

Ask AI About This Document

0Share
PostReddit

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
> Energy, Materials & Industrials DSM - Virginie Boucher-Ferte, BUY, close €81.8, €100 tgt, 22% potential upside • We see Nutrition (68% of EBITDA) as a key growth driver. We forecast a 9% EBITDA 2018-20E CAGR driven by cost cutting, innovation and leverage of its broad portfolio. - A greater proportion of the Nutrition portfolio is in higher-value and faster-growing ingredients and 'solutions' rather than just vitamins. • Up to 30% upside to 18E EBITDA forecast if vitamin price increases are sustained. - Prices are unlikely to revert fully: China's environmental policies are should give structural support in the long term. ■ Full exit from Materials likely, driving portfolio shift towards becoming a pure play in higher-value ingredients. ■ M&A should drive the next phase of development. DSM is likely to use its strong balance sheet (0.5x 17E net debt/EBITDA) to broaden its ingredients portfolio. Deutsche Bank Gil DSM Nutrition organic growth now compares well to peers 10% 9% 8% 7% 6% 5% 4% 3% 2% 1% 0% • • I DSM Nutntion organic growth — — Food Ingredients organic growth average 2009 2010 2011 2012 2013 2014 2015 2016 2017E Source: Deutsche Bank. Company Data Lots of firepower for accretive M &A (DBe synergies 6% of sales) - This would unlock >E20/share of value from EPS accretion and re- 3000 rating. • Trades on 16x 19E PIE, in line with chems but a 33% discount to 2 ingredients. We believe the portfolio shift should prompt re-rating. 15000 ■ Our €100 tgt implies a 20x 19E PIE — still a 15% discount to ingredients. 1000 • Catalysts: Upside through higher value and fast growing ingredients and 500 - "solutions". Portfolio shift optionality. Related DB Research: -500 ()SPA: The path to E100 (and potentially more): upgrade to BUY (Boucher-Fenel nI gredients: 2018 Outlook: Recipe for successi_Boucher-Fertel 2500 - Net Debt (LHS) 2007 2009 2011 Source: DIPUISCI10 Bank, Company Data —Net Deb/EBITDA (RHS) 2013 2015 2017E 2019E 2.50 2.00 1.50 1.00 0.50 0.00 -0.50 :),,ean Equity Focus -January 2018 CONFIDENTIAL - PURSUANT TO FED. R. GRIM. P. 6(e) CONFIDENTIAL DB-SDNY-0086809 SDNY_GM_00232993 EFTA01385523

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.

Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.